NCT06441084View on ClinicalTrials.gov

A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2031

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

NCR300 injection

Subjects will receive at least 1 cycle of NCR300 injection.

Sponsors
All Listed Sponsors
collaborator

Beijing Friendship Hospital

OTHER

lead

Nuwacell Biotechnologies Co., Ltd.

INDUSTRY